Table 1 Demographics of patients receiving hip fracture fixation surgery (n = 126)
Variables | Forteo | Prolia | Total | p-value | |
|---|---|---|---|---|---|
N | 68 | 58 | 126 | ||
Age | 85.8 ± 9.2 | 85 ± 9.5 | 85.5 ± 9.3 | 0.730 | |
Sex | - | - | - | 0.319 | |
Male | 14 (2.6%) | 6 (1.3%) | 20 (15.9%) | ||
Female | 54 (79.4%) | 52 (89.7%) | 106 (84.1%) | ||
BMI | 22.4 ± 4.3 | 22.2 ± 3.3 | 22.3 ± 3.8 | 0.792 | |
FRAX major | 26.7 ± 9.9 | 27.9 ± 11.2 | 27.3 ± 1.5 | 0.664 | |
FRAX hip | 14.8 ± 7.7 | 16.0 ± 1.6 | 15.4 ± 9.1 | 0.606 | |
VAS(PostOP 3 months) | 7.3 ± 0.9 | 7.2 ± 0.9 | 7.3 ± 0.9 | 0.717 | |
Barthel scale (PostOP 3 months) | 33.1 ± 9.9 | 38.8 ± 1.2 | 35.7 ± 1.3 | 0.067 | |
BMD Femur (PostOP 3 months) | -3.0 ± 0.6 | -3.1 ± 0.9 | -3.1 ± 0.7 | 0.749 | |
BMD L1-4 (PostOP 3 months) | -3.1 ± 0.9 | -3.2 ± 1.4 | -3.1 ± 1.1 | 0.747 | |
Previous medication | - | - | - | 0.061 | |
None | 4(5.9%) | 16 (27.6%) | 20 (15.9%) | ||
Prolia | 34 (5.0%) | 24 (41.4%) | 58 (46.0%) | ||
Bisphosphonate | 30 (44.1%) | 18 (31.0%) | 48 (38.1%) | ||
Comorbidity | - | - | - | ||
Dyslipidemia | 6 (8.8%) | 10 (17.2%) | 16 (12.7%) | 0.453 | |
HTN (%) | 40 (58.8%) | 44 (75.9%) | 84 (66.7%) | 0.153 | |
DM (%) | 6 (8.8%) | 16 (27.6%) | 22 (17.5%) | 0.051 | |
CKD (%) | 10 (14.7%) | 8 (13.8%) | 18 (14.3%) | 1.000 | |
CAD (%) | 10 (14.7%) | 4 (6.9%) | 14 (11.1%) | 0.437 | |
Outcome | - | - | - | ||
New fracture occurrence (%) | 2 (2.9%) | 6 (10.3%) | 8 (6.3%) | 0.042* | |
Tolerable side effects (%) | 6 (8.8%) | 3 (5.2%) | 9 (7.1%) | 0.062 | |
Fracture healing period (M) | 12.4 ± 3.8 | 18.2 ± 5.1 | 15.1 ± 4.3 | 0.023* | |